Pricing Log in Create free account

Castle Biosciences, Inc. (CSTL) vs NeoGenomics, Inc. (NEO)

Castle Biosciences, Inc. and NeoGenomics, Inc. are both Diagnostics & Research companies. NeoGenomics, Inc. is the larger, with a market value of $2.1B against $1.0B — 2.0× the size. NeoGenomics, Inc. grew revenue faster over the last twelve months: 11.1% against 9.78%. NeoGenomics, Inc. has the higher net margin (−4.10% vs −6.10%) and the higher return on invested capital (−2.97% vs −3.63%). Across the 18 metrics below, NeoGenomics, Inc. leads on 10 and Castle Biosciences, Inc. on 8.

Valuation

Metric CSTL NEO Diagnostics & Research median
P/E n/m n/m 34.52
P/S 2.77 2.70 4.24
P/B 2.19 2.66 3.42
Price to free cash flow 262.33 n/m 33.51
EV/EBITDA n/m 146.75 23.44
EV/Sales 2.10 3.26 5.18
Earnings yield (2.25%) (1.50%) (1.50%)
Free cash flow yield 0.38% (1.25%) 0.00%

Profitability

Metric CSTL NEO Diagnostics & Research median
Gross margin 77.07% 44.77% 48.32%
Operating margin (7.43%) (6.27%) (5.68%)
Net margin (6.10%) (4.10%) (4.10%)
Free cash flow margin 1.06% (3.37%) 0.00%
Return on equity (4.87%) (3.94%) 0.00%
Return on assets (4.03%) (2.35%) (6.05%)
Return on invested capital (3.63%) (2.97%) 0.00%

Growth

Metric CSTL NEO Diagnostics & Research median
Revenue growth (TTM) 9.78% 11.08% 8.99%
EPS growth (last fiscal year) (233.87%) (35.48%) 20.36%
Revenue growth, 5-year CAGR 40.60% 10.35% 7.30%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CSTL NEO Diagnostics & Research median
Debt to equity 0.01 0.47 0.01
Current ratio 5.28 3.53 2.27
Net debt to EBITDA 46.20 (3.96) 0.68

Dividend

Metric CSTL NEO Diagnostics & Research median
Dividend yield — — 0.67%
Payout ratio — — 0.20

Size

Metric CSTL NEO Diagnostics & Research median
Market cap 1.04b 2.13b 2.22b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack